Modalis Therapeutics Corporation Statistics
Want to see JP:4883 full AI Analyst Report?
Modalis Therapeutics Corporation (4883) Stock Statistics & Valuation Metrics
Total Valuation
Modalis Therapeutics Corporation has a market cap or net worth of JPY 3.73B. The enterprise value is JPY 842.94M.
- Market Cap
- JPY 3.73B
- Enterprise Value
- JPY 842.94M
Share Statistics
Modalis Therapeutics Corporation has 115,954,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 115,954,100
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Modalis Therapeutics Corporation’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -78.17%.
- Return on Equity (ROE)
- -0.77
- Return on Assets (ROA)
- -0.73
- Return on Invested Capital (ROIC)
- -78.17%
- Return on Capital Employed (ROCE)
- -0.78
- Revenue Per Employee
- 0
- Profits Per Employee
- -126.63M
- Employee Count
- 17
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Modalis Therapeutics Corporation is -1.41. Modalis Therapeutics Corporation’s PEG ratio is -0.05.
- PE Ratio
- -1.41
- PS Ratio
- 0.00
- PB Ratio
- 1.30
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Modalis Therapeutics Corporation had revenue of 0 and earned -2.15B in profits. Earnings per share was -27.86.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -2.21B
- Pretax Income
- -2.15B
- Net Income
- -2.15B
- EBITDA
- -2.21B
- Earnings Per Share (EPS)
- -27.86
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Modalis Therapeutics Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -61.34%
Stock Price Statistics
- Beta
- 0.92
- 52-Week Price Change
- -53.73%
- 50-Day Moving Average
- 30.52
- 200-Day Moving Average
- 42.65
- Relative Strength Index (RSI)
- 47.88
- Average Volume (3m)
- 1.89M
Important Dates
Modalis Therapeutics Corporation upcoming earnings date is Feb 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Feb 15, 2027
- Ex-Dividend Date
- ―
Financial Position
Modalis Therapeutics Corporation as a current ratio of 21.46, with Debt / Equity ratio of 0.00%
- Current Ratio
- 21.46
- Quick Ratio
- 21.46
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.27
- Interest Coverage Ratio
- -788.80
Taxes
In the past 12 months, Modalis Therapeutics Corporation has paid 1.54M in taxes.
- Income Tax
- 1.54M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Modalis Therapeutics Corporation EV to EBITDA ratio is -0.59, with an EV/FCF ratio of 0.00.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.59
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Modalis Therapeutics Corporation has JPY 3.02B in cash and marketable securities with JPY 270.00M in debt, giving a net cash position of JPY 2.75B billion.
- Cash & Marketable Securities
- JPY 3.02B
- Total Debt
- JPY 270.00M
- Net Cash
- JPY 2.75B
- Net Cash Per Share
- JPY 23.68
- Tangible Book Value Per Share
- JPY 26.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Modalis Therapeutics Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 25.34%
Scores
- Smart Score
- ―
- AI Score
- 43

